TG Therapeutics FY2025 EPS Decreased by Cantor Fitzgerald

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the biopharmaceutical company will post earnings of $0.58 per share for the year, down from their prior estimate of $1.08. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business’s revenue was up 90.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.07) EPS.

TGTX has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.80.

TG Therapeutics Stock Performance

TGTX opened at $33.64 on Thursday. TG Therapeutics has a 12-month low of $15.16 and a 12-month high of $46.48. The company has a market cap of $5.34 billion, a price-to-earnings ratio of -336.37 and a beta of 2.21. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company’s 50 day moving average is $38.90 and its 200 day moving average is $33.56.

Hedge Funds Weigh In On TG Therapeutics

Large investors have recently made changes to their positions in the business. Vermillion Wealth Management Inc. purchased a new position in TG Therapeutics in the 4th quarter worth approximately $30,000. NBC Securities Inc. raised its position in shares of TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 823 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 433 shares in the last quarter. Quadrant Capital Group LLC boosted its position in shares of TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 975 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 371 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.